Recently Featured

FDALabel: Full-Text Search of Drug Product Labeling

July 13, 2026
The FDA has launched the FDALabel Database, a comprehensive web-based tool that enables customizable searches across a repository of over 150,000 labeling documents for FDA-approved drug products. This includes a wide array of items such as human and animal prescription and over-the-counter drugs, biological products, and medical devices. The introduction of this tool marks a…

Acadia’s Drug Receives Approval from European Regulators on Second Attempt

July 13, 2026
Acadia Pharmaceuticals has successfully secured approval from European regulators for its drug, a significant turnaround following an earlier rejection. The Committee for Medicinal Products for Human Use (CHMP) endorsed the marketing authorization, marking a pivotal moment for Acadia as it navigates the complex European pharmaceutical landscape. This approval comes at a time when the CHMP…

CDER and Office of the Chief Scientist Formalize Cosmetic Agreement

July 13, 2026
The Center for Drug Evaluation and Research (CDER) has established a formal working agreement with the Office of the Chief Scientist, aimed at enhancing the regulatory framework surrounding cosmetic products. This collaboration is designed to streamline processes and improve compliance mechanisms, reflecting a growing recognition of the need for robust oversight in the cosmetic sector.…

Sanofi Under Antitrust Probe as European Commission Kicks Off Formal Proceedings

July 13, 2026
The European Commission has initiated formal antitrust proceedings against Sanofi, focusing on the company’s marketing practices related to its flu vaccine, Efluelda, intended for at-risk seniors. This investigation marks a significant step in regulatory scrutiny within the pharmaceutical sector, particularly concerning how major players promote essential healthcare products. Contextually, the probe reflects growing concerns among…

Ongoing Cases